Across TCGA pan-cancer cohorts, ANTXRL Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ANTXRL data layer compared with 22 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher ANTXRL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANTXRL expression acts as an unfavorable survival marker.
ESCA are the cancer types where ANTXRL Mutation most reproducibly stratifies survival.